A novel drug has been shown in preclinical studies to be effective in improving grip strength and motor coordination in a model of Parkinson’s disease.
Jupiter Neurosciences, a clinical-stage pharmaceutical company focused on the treatment of central nervous system (CNS) disorders and rare diseases, has announced preclinical data from its proprietary drug product, JOTROL™, for the treatment of Parkinson’s Disease (PD).
The company recently completed preclinical studies in a mouse model of PD, in collaboration with scientists Shaun Brothers, PhD, MBA and Candace Carriere, PhD at the University of Miami School of Medicine.
This model of PD mimics many aspects of the disease utilising a unilateral injection of a neurotoxin precursor that elicits nigral cell loss, striatal dopamine loss and behaviour deficits similar to physiological characteristics of human Parkinson’s disease.
Results showed statistically significant positive outcomes, particularly in the endpoint of enhanced grip strength.
Grip strength is a key physical manifestation of the disease, a motor score used to measure the severity and progression of PD.
Improvement of grip strength is a disease modifying breakthrough for patients suffering with the diseaase.
Additional findings include JOTROL™ significantly improving an outcome used to evaluate motor coordination, rotarod performance; significantly improving behavioural characteristics induced in the animal model; as well as being generally safe and well tolerated.
Alison Silva, President & CBO, commented: “These exciting data support our nomination of JNS115 as our next development project and our entrance into the PD population with JOTROL™. JNS115 is a clear strategic priority for the Company.
“This research demonstrates the neuroprotectant abilities of JOTROL™ as a potential treatment to prevent onset and progression of PD symptoms. We look forward to advancing this program with a partner, as well as continuing to advance our internal rare disease and ongoing MCI/ early Alzheimer’s Disease programs.”